ArticlePharmacognosy magazine
Quantitative Analysis and In vitro Anti-inflammatory Effects of Gallic Acid, Ellagic Acid, and Quercetin from Radix Sanguisorbae.
Article in Pharmacognosy magazine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 58 citations in OpenAlex.
- Therapeutic Potential of Ziyuglycosides fromDrug design, development and therapy · 2026Review
- Anti-Inflammatory and Immunomodulatory Effects of Aqueous Extracts from Green Leaves and Rhizomes ofMolecules (Basel, Switzerland) · 2025Article
- Phytochemical Analysis and Phytometabolomic Profiling ofInternational journal of molecular sciences · 2025Article
- Investigation of In Vitro and In Silico Anti-Inflammatory Potential ofInternational journal of molecular sciences · 2025Article
- Therapeutic Potential of Ellagic Acid in Liver Diseases.Molecules (Basel, Switzerland) · 2025Review
- In vitro study of the treatment of dentin hypersensitivity with gallic acid combined with sodium fluoride.BMC oral health · 2024Article
- The Potential Health Benefits of Gallic Acid: Therapeutic and Food Applications.Antioxidants (Basel, Switzerland) · 2024Review
- Unlocking the Therapeutic Potential of Ellagic Acid for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.Antioxidants (Basel, Switzerland) · 2024Review
- Anti-Inflammatory and Anti-Adipocyte Dysfunction Effects ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Gallic Acid Alleviates Injury of Intestine Induced by Escherichia Coli: Protective Role of Metalloproteinase and Antioxidants on Small Intestine In-vivo.Galen medical journal · 2024Article
- Article
- Olive Oil as a Transport Medium for Bioactive Molecules of Plants?-An In Situ Study.Molecules (Basel, Switzerland) · 2023Article
- Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase.Nutrients · 2023Article
- Regulating Th17/Treg Balance Contributes to the Therapeutic Effect of Ziyuglycoside I on Collagen-Induced Arthritis.International journal of molecular sciences · 2022Article
- Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocin-diabetic rats by activating AMPK.Pharmaceutical biology · 2022Article
- Review
- Technologies for Solubility, Dissolution and Permeation Enhancement of Natural Compounds.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Anti-inflammatory and analgesic properties of Moroccan medicinal plants: Phytochemistry,Journal of pharmaceutical analysis · 2022Review
- Serum Metabolomics Analysis of the Anti-Inflammatory Effects of Gallic Acid on Rats With Acute Inflammation.Frontiers in pharmacology · 2022Article
- Gallic Acid and Diabetes Mellitus: Its Association with Oxidative Stress.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadix Sanguisorbae has long been used to treat diarrhea, enteritis, duodenal ulcers, and internal hemorrhage.
objectiveWe investigated the in vitro anti-inflammatory effects of Radix Sanguisorbae and performed quantitative analyses of three marker components, namely gallic acid, ellagic acid, and quercetin, using high-performance liquid chromatography coupled with a photodiode array detector. MATERIALS AND
methodsThe three marker components were separated using a reversed-phase Gemini C18 analytical column maintained at 40°C by the gradient elution with two solvent systems. We examined the biological effects of the three marker compounds, gallic acid, ellagic acid, and quercetin, by determining their anti-inflammatory activities in the murine macrophage cell line RAW 264.7.
resultsAll of the marker compounds exhibited inhibitory effects on prostaglandin E2 production in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages, with no cytotoxicity. Particularly, ellagic acid significantly inhibited production of the proinflammatory cytokines tumor necrosis factor alpha and interleukin-6 in LPS-treated RAW 264.7 cells.
conclusionOur results suggest that ellagic acid is the most potent bioactive phytochemical component of radix Sanguisorbae in the treatment of inflammatory diseases. SUMMARY: Established high-performance liquid chromatography method was applied in the quantitative analysis of gallic acid, ellagic acid, and quercetin present in an extract from radix SanguisorbaeAmong the three compounds, the ellagic acid.(7.65.mg/g) is main component in radix SanguisorbaeEllagic acid significantly inhibited production of the proinflammatory cytokines tumor necrosis factor alpha and interleukin-6 in lipopolysaccharide-treated RAW 264.7 cells. Abbreviations used: HPLC: High-performance liquid chromatography, PDA: Photodiode array, TNF-α: Tumor necrosis factor alpha, IL: Interleukin, LPS: Lipopolysaccharide, PGE2: Prostaglandin E2, NSAIDs: Nonsteroidal anti-inflammatory drugs, COX: Cyclooxygenase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.